Details for New Drug Application (NDA): 215177
✉ Email this page to a colleague
NDA 215177 describes ESCITALOPRAM OXALATE, which is a drug marketed by Rising, Amneal Pharms, Antrim Pharms Llc, Aurobindo Pharma Ltd, Chartwell Molecular, Hetero Labs Ltd Iii, Macleods Pharms Ltd, Sun Pharma Canada, Accord Hlthcare, Aiping Pharm Inc, Ascent Pharms Inc, Chartwell Rx, Graviti Pharms, Hikma Pharms, Invagen Pharms, Jubilant Cadista, Novitium Pharma, Prinston Inc, Teva Pharms Usa, Torrent Pharms Ltd, and Zydus Lifesciences, and is included in twenty-four NDAs. It is available from forty-three suppliers. Additional details are available on the ESCITALOPRAM OXALATE profile page.
The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
The generic ingredient in ESCITALOPRAM OXALATE is escitalopram oxalate. There are twenty-six drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the escitalopram oxalate profile page.
Summary for 215177
| Tradename: | ESCITALOPRAM OXALATE |
| Applicant: | Ascent Pharms Inc |
| Ingredient: | escitalopram oxalate |
| Patents: | 0 |
Pharmacology for NDA: 215177
| Mechanism of Action | Serotonin Uptake Inhibitors |
Suppliers and Packaging for NDA: 215177
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 215177 | ANDA | Ascent Pharmaceuticals, Inc | 43602-473 | 43602-473-10 | 1000 TABLET in 1 BOTTLE (43602-473-10) |
| ESCITALOPRAM OXALATE | escitalopram oxalate | TABLET;ORAL | 215177 | ANDA | Ascent Pharmaceuticals, Inc | 43602-473 | 43602-473-30 | 30 TABLET in 1 BOTTLE (43602-473-30) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 5MG BASE | ||||
| Approval Date: | Jul 15, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Jul 15, 2025 | TE: | AB | RLD: | No | ||||
Profile for product number 003
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 20MG BASE | ||||
| Approval Date: | Jul 15, 2025 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
